Vyanka Mezcord, Jenny Escalante, Brent Nishimura, German M Traglia, Rajnikant Sharma, Quentin Vallé, Marisel R Tuttobene, Tomás Subils, Ingrid Marin, Fernando Pasteran, Luis A Actis, Marcelo E Tolmasky, Robert A Bonomo, Gauri Rao, María S Ramirez
Infections caused by Carbapenem-resistant Acinetobacter baumannii (CRAB) isolates, such as hospital-acquired pneumonia (HAP), bacteremia, and skin and soft tissue infections, among others, are particularly challenging to treat. Cefiderocol, a chlorocatechol-substituted siderophore antibiotic, was approved by the U.S. Food and Drug Administration (FDA) in 2019 and prescribed for the treatment of CRAB infections. Despite the initial positive treatment outcomes with this antimicrobial, recent studies reported a higher-than-average all-cause mortality rate in patients treated with cefiderocol compared to the best available therapy...
July 21, 2023: International Journal of Molecular Sciences